Entries |
Document | Title | Date |
20080275213 | Synthesis of Carbohydrate-Templated Amino Acids and Methods of Using Same - The present invention generally relates to tetrahydropyranyl-derivatized amino acids, their syntheses and their incorporation into peptides and peptidomimetics. The tetrahydropyran moiety constrains the side chain of an amino acid, thereby providing a molecule that may act as a sugar- or amino acid-mimetic as well as a scaffold for combinatorial synthesis. | 11-06-2008 |
20080300382 | Immunogenic Complexes, Preparation Method Thereof And Use Of Same In Pharmaceutical Compositions - The invention relates to a method of improving the immunogenicity of an immunogen, antigen or hapten, by means of coupling with a small support peptide. More specifically, the invention relates to a method of preparing an immunogenic complex, as well as the complexes that can be obtained using one such method, and to the use of said complexes as a medicament in order to increase the immunogenicity of an immunogen. The invention comprises, for example, a support peptide which is coupled with a peptide from protein G of the respiratory syncytial virus (RSV) and to the use thereof as a vaccine for the treatment of respiratory infections linked to RSV. | 12-04-2008 |
20080312407 | Glycopeptide phosphonate derivatives - Disclosed are glycopeptides that are substituted with one or more substituents each comprising one or more phosphono groups; and pharmaceutical compositions containing such glycopeptide derivatives. The disclosed glycopeptide derivatives are useful as antibacterial agents. | 12-18-2008 |
20080312408 | Method of Separating a Peptidoglycan Recognition Protein From a Hemolymph Tenebrio Molitor Larvae - Provided is a method of separating a peptidoglycan-recognition protein from the hemolymph of | 12-18-2008 |
20090048427 | HYBRIDIZATION AND MISMATCH DISCRIMINATION USING OLIGONUCLEOTIDES CONJUGATED TO MINOR GROOVE BINDERS - Conjugates between a minor groove binding molecule, such as the trimer of 1,2-dihydro-(3H)-pyrrolo[3,2-e]indole-7-carboxylate (CDPI | 02-19-2009 |
20090082547 | COMPOSITIONS FOR ENHANCING TRANSPORT OF MOLECULES INTO CELLS - Compositions and methods for enhancing delivery of molecules, e.g. biological agents, into cells are described. The composition is a conjugate of the biological agent, preferably a nucleic acid analog having a substantially uncharged backbone, covalently linked to a peptide transporter moiety as described. Conjugation of the peptide transporter to a substantially uncharged nucleic acid analog, such as a morpholino oligomer, is also shown to enhance binding of the oligomer to its target sequence and enhance antisense activity. | 03-26-2009 |
20090203877 | X-RAY-DENSE CONJUGATE - The present invention relates to an X-ray dense conjugate, the use of the conjugate for producing a diagnostic and therapeutic composition, a pharmaceutical and/or diagnostic composition, which comprises said conjugate, a method for the diagnostic and/or analytical treatment of biological material or a living being, and a method for the therapeutic treatment of a living being. | 08-13-2009 |
20090215982 | GLYCOPEPTIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME - Disclosed are derivatives of glycopeptide compounds having at least one substituent of the formula: | 08-27-2009 |
20090247732 | Synthesis of glycopeptides with superior pharmacokinetic properties - The present invention relates to novel glycopeptides having improved pharmacokinetic properties, improved stability, methods of preparing said novel glycopeptides, and methods to use said novel glycopeptides. | 10-01-2009 |
20090253895 | Printable Materials - The present invention provides compounds of the general formula I, and uses thereof for printing electronic components such as wires, resistors and LEDs. | 10-08-2009 |
20090275729 | MICRORNA AND METHODS FOR INHIBITING SAME - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules. | 11-05-2009 |
20090312521 | Antibiotic drosocin derivatives - The invention concerns derivatives of drosocin which have an increased half-life in mammalian serum by substituting one or more of the amino acid residues of wild type drosocin with another amino acid or a peptidomimetic moiety capable of replacing said amino acid. These derivatives can be used for antibiotic therapy or in a bacteriocidal composition. | 12-17-2009 |
20100016546 | Therapeutic Peptide-Polysaccharide Biomaterials - Peptide-polysaccharide conjugates may be created by linking at least one peptide to a polysaccharide. The peptide may be a defensin having at least a portion of the amino acid sequence of human-β-defensin-3. The portion may be the last 10-14 residues of the amino acid sequence. The polysaccharide may be functionalized with at least one R group prior to the linkage to aid in the linkage. | 01-21-2010 |
20100036090 | GLYCOALKALOID REMOVAL - The invention relates to a process for the removal of glycoalkaloids, in particular from process streams such as those encountered during isolation of proteins from potatoes. | 02-11-2010 |
20100069607 | METHOD OF COVALENTLY LINKING A CARBOHYDRATE OR POLYALKYLENE OXIDE TO A PEPTIDE, PRECURSORS FOR USE IN THE METHOD AND RESULTANT PRODUCTS - A glycopeptide of the formula S-L-X—P, wherein: S is selected from an optionally protected monosaccharide, an optionally protected polysaccharide, a polyalkylene oxide chain and a group of the formula II, wherein R | 03-18-2010 |
20100081786 | Homogeneous Erythropoietin and Other Peptides and Proteins, Methods and Intermediates for Their Preparation - The present invention provides isolated homogeneous polyfunctionalized proteins (e.g., erythropoietin), isolated glycopeptides, and a method for preparing polyfunctionalized peptides and/or proteins via cysteine-free native chemical ligation. In certain embodiments, the invention provides an isolated homogeneous polyfunctionalized protein having the structure (I). In certain other embodiments, the invention provides an isolated glycopeptide having Formula (II). In certain other embodiments, the inventive method is a method for preparing a polyfunctionalized peptide comprising a peptidic backbone made up of four or more amino acids, wherein two or more non-adjacent amino acids are independently substituted with a moiety having the structure (III)-LH. wherein A and L1 are as defined herein. | 04-01-2010 |
20100093974 | Linkers and Co-Coupling Agents for Optimization of Oligonucleotide Synthesis and Purification on Solid Supports - A method of modulation of synthesis capacity on and cleavage properties of synthetic oligomers from solid support is described. The method utilizes linker molecules attached to a solid surface and co-coupling agents that have similar reactivities to the coupling compounds with the surface functional groups. The preferred linker molecules provide an increased density of polymers and more resistance to cleavage from the support surface. The method is particularly useful for synthesis of oligonucleotides, oligonucleotides microarrays, peptides, and peptide microarrays. The stable linkers are also coupled to anchor molecules for synthesis of DNA oligonucleotides using on support purification, eliminating time-consuming chromatography and metal cation presence. Oligonucleotides thus obtained can be directly used for mass analysis, DNA amplification and ligation, hybridization, and many other applications. | 04-15-2010 |
20100121028 | Hydrolysable Polymeric FMOC- Linker - The invention relates to Fmoc (9-fluorenyl-methoxycarbonyl)-based polymeric conjugates. These conjugates are useful for extending the in-vivo circulation of protein and peptide drugs. | 05-13-2010 |
20100184947 | MOLECULES FOR TARGETING COMPOUNDS TO VARIOUS SELECTED ORGANS, TISSUES OR TUMOR CELLS - The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detectable agent. In addition the invention provides methods to diagnose or treat neuronal or neuromuscular disease, or a pathology of the brain, or a tumor of neuronal or neuroectodermal origin, by administrating to a subject having or suspected of having a pathology a molecule or conjugate that homes to, binds to and is taken up by the brain cells or neuronal cells, or by the tumor cells of neuronal or neuroectodermal origin. The invention also provides a method of identifying and measuring neurite growth in neuronal cells. | 07-22-2010 |
20100184948 | MOLECULES FOR TARGETING COMPOUNDS TO VARIOUS SELECTED ORGANS OR TISSUES - The invention provides conjugates, comprising an organ, tissue or tumor cell homing molecule linked to a moiety. Such a moiety can be, for example, an oligonucleotide, small interfering RNA, gene, virus, protein, pharmaceutical or detectable agent. In addition the invention provides methods to diagnose or treat a pathology of the muscle or heart, by administrating to a subject having or suspected of having a pathology a molecule or conjugate that homes to, binds to and is taken up by the muscle cells or heart cells. | 07-22-2010 |
20100190958 | PURE VANCOMYCIN HYDROCHLORIDE - The new pure vancomycin hydrochloride substantially free of impurities known in commercially available products is described. The term “substantially free of impurities” designates a purity of vancomycin hydrochloride between about 97% and about 99%, particularly between about 98% and about 99%, preferably about 99%, as determined by HPLC analytical method as directed in U.S.P., NF 27th revision, 22 (2004). The new pure vancomycin hydrochloride (vancomycin B hydrochloride) contains less than 0.7% of total impurities, namely, only one impurity exceeds 0.3%. The new process for the purification of crude vancomycin by displacement chromatography is described by which the desired pure antibiotic according to the present invention is produced, based on the finding that high purity of the vancomycin hydrochloride is obtained using low selected pH values of the mobile phase between 3.9 and 4.2. Vancomycin hydrochloride is the known antibiotic which is used for the treatment of severe staphylococcal infections, especially those caused by methicillin-resistant staphylococcal strains. | 07-29-2010 |
20100190959 | VANCOMYCIN B HYDROCHLORIDE CRYSTALLINE FORM 1 - Vancomycin B Hydrochloride Crystalline Form 1, compositions containing it and methods of prevention or treatment of bacterial infections using it are disclosed. | 07-29-2010 |
20100204444 | MULTIFUNCTIONAL PROTEIN SIMULTANEOUSLY DELIVERING ANTIBODIES AND NANOPARTICLES - The present invention relates to a polypeptide structure which can simultaneously deliver an antibody and a nanoparticle into cells, more specifically, to a polypeptide structure for intracellular delivery of an antibody and a nanoparticle, which comprises a nanoparticle-binding region, an antibody-binding region and a signaling capable of delivering substances into cells. | 08-12-2010 |
20100216971 | RNAi Inhibition of Alpha-ENaC Expression - The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides. | 08-26-2010 |
20100216972 | RNAi Inhibition of Alpha-ENaC Expression - The invention relates to compositions and methods for modulating the expression of alpha-ENaC, and more particularly to the downregulation of alpha-ENaC expression by chemically modified oligonucleotides. | 08-26-2010 |
20100222546 | METHODS FOR THE PREPARATION OF FUNCTIONALIZED PEPTIDES, PROTEINS AND CARBOHYDRATES AND THEIR CONJUGATES - The present invention relates to methods for ligation or derivatization of peptides, amino acids, and carbohydrates utilizing a chalcogen-based reactant, a peptide reactant, an amino acid reactant, a chalcogen-containing peptide reactant, a chalcogen-containing amino acid reactant, or a combination of two or more of the foregoing reactants substantially as described herein. | 09-02-2010 |
20100228005 | Process for the Purification of Macrolide Antibiotics - The present invention concerns a process for the purification of macrolide antibiotics. More specifically it concerns a process for the purification of macrolide antibiotics that result in a white powder. The powder remains white also after some time of storage. The process of the present invention is performed by dissolving the macrolide antibiotics, e.g. commercial vancomycin hydrochloride, in water and subjecting the solution to ultrafiltration with a membrane having nominal retention lower than 30,000 Da, preferably of 10,000 Da. The purified solution is preferably concentrated by reversed osmosis and then lyophilized at the optimized conditions of pressure and temperature to obtain a white powder. | 09-09-2010 |
20100249372 | Botulinum neurotoxin a receptor and the use thereof - The present invention is based on the identification of synaptic vessel glycoprotein SV2 as the BoNT/A receptor and the further identification of various BoNT/A-binding fragments of SV2. The disclosure here provides new tools for diagnosing and treating botulism. | 09-30-2010 |
20100261872 | Factor VIII: remodeling and glycoconjugation of factor VIII - The invention includes methods and compositions for remodeling a peptide molecule, including the addition or deletion of one or more glycosyl groups to a peptide, and/or the addition of a modifying group to a peptide. | 10-14-2010 |
20100261873 | GLYCOPROTEINS AND GLYCOSYLATED CELLS AND A METHOD FOR THE PREPARATION OF THE SAME - The present application discloses novel glycoproteins and a related glycosylcarbamoylation methodology suitable for the preparation of glycopeptides (in particular glycoproteins and glycosylated cells), as well as the use of such glycoproteins in medicine, e.g. as pharmaceuticals and diagnostics or in diagnostic kits. The method for the preparation of a carbohydrate-peptide conjugate comprises reacting a cyclic carbamate (1) (wherein R | 10-14-2010 |
20100261874 | SYNTHETIC GENES FOR PLANT GUMS AND OTHER HYDROXYPROLINE RICH GLYCOPROTEINS - A new approach in the field of plant gums is described which presents a new solution to the production of hydroxyproline(Hyp)-rich glycoproteins (HRGPs), repetitive proline-rich proteins (RPRPs) and arabino-galactan proteins (AGPs). The expression of synthetic genes designed from repetitive peptide sequences of such glycoproteins, including the peptide sequences of gum arabic glycoprotein (GAUP), is taught in host cells, including plant host cells. | 10-14-2010 |
20100273978 | Modified polypeptides suitable for acceptace of amino acid substited molecules - The invention provides compositions and methods of identifying, modifying and producing modified target molecules, including therapeutic molecules by modification with non-natural amino acids. Certain aspects of the invention include methods of adding a chemical moiety to a target molecule, and the compositions resulting therefrom. Certain aspects of the invention also relate to kits for identifying, modifying and producing modified target molecules described herein. | 10-28-2010 |
20100286364 | GLYCOSYLATED GLYCOPEPTIDE ANTIBIOTIC DERIVATIVES - The present invention provides novel glycopeptides antibiotic derivatives. | 11-11-2010 |
20100298529 | MANUFACTURE AND USE OF MODIFIED POLYSACCHARIDE CHITOSAN BONDS AND A PROCESS TO IMPROVE THE PREPARATION OF HES-MEDICINAL SUBSTANCE COMPOUNDS - The invention relates to a bonding product suitable as a carrier for medicinal substances and to the compound derived therefrom that carries medicinal substances. The invention further relates to a process and device for preparing such bonding products and compounds. Further, the invention relates to a pharmaceutical composition containing such bonding products and compounds, and to the use thereof for preparing an infusible medicament for treating a disease. | 11-25-2010 |
20100298530 | Photoresponsive Base Having Triazole Skeleton - To provide a photocrosslinkable compound and a photocrosslinking agent which are capable of ligation of nucleic acids within a short period of time compared to the conventional cases, and to which modifications depending on the intended use can easily be made, and a method of producing the photocrosslinking agent. Nucleic acids including a group represented by the formulae I, III, IV, or V as a nucleobase; a photocrosslinking agent including the nucleic acids, a method of producing nucleic acids by reacting nucleic acids including a group represented by the formulae VI, VII, VIII, or IX as a nucleobase with an aromatic azidated product represented by the formula X. | 11-25-2010 |
20100305303 | INHIBITING AGENT FOR INHIBITION OF ANGIOGENESIS, A METHOD FOR PREPARING THE AGENT, A METHOD FOR MODIFYING THE AGENT AND ITS USE FOR MANUFACTURING A MEDICAMENT FOR TREATING TUMOR - a highly efficient antiangiogenesis agent, which is a polypeptide for inhibition of angiogenesis Ile-Val-Arg-Arg-Ala-Asp-Arg-Ala-Ala-Val-Pro, connected with a polypeptide containing Arg-Gly-Asp on its one end or two ends is provided. The inhibiting agent can be synthesized or gene engineered. It also relates to a physiochemical method for modifying the antiangiogenesis agent. Polypeptides with weight percentage of 1-70% preferably about 20-50% are mixed with 20%-95% polyethylene glycol, or heparin, or dextran, or polyvinylpyrrolidone, or polyethylene glycol-poly-amino acid copolymer, or palmitic acid or poly-sialic acid or liposomes solutions; preferably about 50-93% of the above modified substances are fully mixed even and shaken at a shaker at 4° C.-40° C., preferably 25° C.-37° C. for more than 10 min, and the modified substances are separated through appropriate methods. Furthermore, it still relates to the use of the above polypeptides and the polypeptide modified substances for manufacturing medicaments for treating human solid tumors. | 12-02-2010 |
20110009596 | PROCESS FOR THE PREPARATION OF N-PROTECTED-DECYLAMINOETHANAL - Compounds useful in the preparation of telavancin, for example, were prepared. These compounds include decylaminoethanal dialkyl acetals and N-protected decylaminoethanal dialkyl acetals, imidazolidine derivatives, and N-protected-decylaminoethanal. | 01-13-2011 |
20110021745 | ULTRA-SMALL CHITOSAN NANOPARTICLES USEFUL AS BIOIMAGING AGENTS AND METHODS OF MAKING SAME - A method of making ultra-small chitosan nanoparticles having a size range of approximately 10-20 nm, includes preparing a first microemulsion containing effective amounts of cyclohexane, n-hexanol, chitosan polymer and a nonionic surfactant. A second microemulsion is prepared containing effective amounts of cyclohexane, n-hexanol, tartaric acid, EDC, n-hydroxysuccinimide, and a nonionic surfactant. The method continues by reacting the first and second microemulsions for a time sufficient to form the ultra-small chitosan nanoparticles and recovering the nanoparticles from the reacted microemulsion. The chitosan polymer may be crosslinked and may also be tagged with a fluorescent compound, a radio-opaque compound, a paramagnetic ion, a ligand specific for a predetermined biologic target, a drug, and combinations thereof. | 01-27-2011 |
20110034670 | BISUBSTRATE INHIBITORS OF PROTEIN KINASES AS THERAPEUTIC AGENTS - A bisubstrate inhibitor of Src kinases, having a nucleotide or N-heteroaromatic moiety; and a peptide/phosphopeptide, peptidomimetic, or phosphopeptide mimic moiety. The moieties are linked by a rigid or a flexible linker. The nucleotide or N-heteroaromatic moiety is ATP, ATP-mimics, N-heteroaromatics including purine-based derivatives, pyrimidine-based derivatives such as 2,4-diamino-5-substituted pyrimidine derivatives, pyrazole[3,4-d]pyrimidine derivatives, pyrrolo[2,3-d]pyrimidine derivatives, pyrido[2,3-d]pyrimidine derivatives, amino-substituted dihydropyrimido[4,5-d]pyrimidinone derivatives, thieno- and furo-substituted derivatives, quinazoline derivatives, and quinoline derivatives, and several natural products such as aminogenistein. The phosphopeptide mimics comprise phosphonate-based phosphotyrosine mimetics such as phosphonomethylphenylalanine (Pmp) and its analogues, carboxylic acid-based phosphotyrosine mimetics such as malonyltyrosine or phenylalanine analogues and their derivatives such as carboxymethyl phenylalanine, uncharged pTyr mimetics, and conformationally constrained peptides. The phosphopeptide or phosphopeptide mimics inhibits the Src kinases SH2 domain. | 02-10-2011 |
20110060121 | METHOD OF PREPARING GLYCOPEPTIDES - A method is provided for the synthesis of glycopeptides using a sugar assisted ligation strategy, wherein an N-terminal peptide portion in the form of a thioester is coupled with a C-terminal peptide portion bearing a carbohydrate moiety comprising a thiol group. | 03-10-2011 |
20110060122 | PROCESS FOR PREPARING GLYCOPEPTIDE PHOSPHONATE DERIVATIVES - Disclosed are processes for preparing glycopeptide phosphonate derivatives having an amino-containing side chain. Several of the process steps are conducted in a single reaction vessel without isolation of intermediate reaction products, thereby generating less waste and improving the overall efficiency and yield of the process. | 03-10-2011 |
20110060123 | CHARGE CONVERSIONAL TERNARY POLYPLEX - Disclosed is a polymer composite (polyplex) that contains nucleic acid, a cationic polymer, and an anionic polymer. The anionic polymer covers the surface of the composite comprising the cationic polymer and nucleic acid, has a negative charge at neutral pH, and can change so as to have a positive charge at mildly acidic pH. | 03-10-2011 |
20110087003 | GLYCOPEPTIDE COMPOSITIONS - The invention include glycopeptides having a glycoside and a peptide covalently bound through an amide bond. The glycopeptides may also include a diagnostic or therapeutic agent bound to the glycopeptide. A metal, such as a radionuclide, may also be chelated to the glycopeptide. Specific embodiments of the invention relate to glycopeptides made of chitosan covalently bound to a poly(amino acid) such as poly(glutamic acid) or poly(aspartic acid). Diagnostic agents conjugated to the glycopeptide may facilitate imaging. Specific therapeutic agents that may be conjugated to the glycopeptide include anticancer drugs, rheumatoid arthritis drugs, anticoagulants, anti-angiogenesis drugs, apoptosis drugs, osteoporosis drugs, steroids, and anti-inflammatory drugs. Some agents, such as radionuclides, may have both diagnostic and therapeutic effects. The glycopeptides may be made by combining a glycoside and a peptide in the presence of a carbodiimide and an acid group activator to form an amide bond between the glycoside and the peptide. | 04-14-2011 |
20110098441 | Label target and labeling reagents comprising backbones with at least two consecutive peptide bonds - This invention provides for labeling reagents, labeled targets and processes for preparing labeling reagents. The labeling reagents can take the form of cyanine dyes, xanthene dyes, porphyrin dyes, coumarin dyes or composite dyes. These labeling reagents are useful for labeling probes or targets, including nucleic acids and proteins. These reagents can be usefully applied to protein and nucleic acid probe based assays. They are also applicable to real-time detection processes. | 04-28-2011 |
20110112276 | MUTATED IMMUNOGLOBULIN-BINDING PROTEIN - The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine. | 05-12-2011 |
20110118438 | CYANINE-TYPE COMPOUNDS HAVING AN ALKYNYL LINKER ARM - Cyanine-type fluorescent dyes modified with an alkynyl linker arm of formula (I), suitable for the conjugation of biomolecules, such as for example nucleosides, nucleotides, oligonucleotides, nucleic acids, proteins, peptides, vitamins and hormones. A method and intermediates for the synthesis of the alkynyl cyanines of the invention are also described, as well as alkynyl cyanine-biomolecule conjugates and methods for preparing thereof. The alkynyl cyanines can be advantageously used as markers for biomolecules or as quenchers. | 05-19-2011 |
20110137010 | PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, EFFICIENT RNA SYNTHESIS AND CONVENIENT INTRODUCTION OF 3'-END LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA - The present invention provides building blocks and methods for synthesizing very pure RNA in a form that can efficiently be modified at the 3′ end. Reverse RNA monomer phosphoramidites have been developed for RNA synthesis in 5′→3′ direction, leading to very clean oligo synthesis that allows for the introduction of various modifications at the 3′-end cleanly and efficiently. Higher coupling efficiency per step have been observed during automated oligo synthesis with the reverse RNA amidites disclosed herein, resulting in a greater ability to achieve higher purity and produce very long oligonucleotides. The use of the reverse RNA phosphoramidites in the synthetic process of this invention leads to oligonucleotides free of N+1 species. | 06-09-2011 |
20110137011 | HYPERGLYCOSYLATED HUMAN COAGULATION FACTOR IX - The invention relates to hyperglycosylated human coagulation factor IX polypeptides, to processes for preparing said polypeptides, to pharmaceutical compositions comprising said polypeptides and to the use of the compounds for the treatment of diseases alleviated by human coagulation factor IX, in particular, but not exclusively hemophilia. | 06-09-2011 |
20110172392 | METHOD FOR PRODUCING PEPTIDE - The present invention provides a method for producing a peptide, characterized in that it comprises converting an —SH group of a peptide comprising an amino acid residue having the —SH group to an —OH group, wherein said method comprises the following steps (a) to (c): (a) allowing an —SH group in a peptide to react with a methylating agent to convert the —SH group to an —SMe group; (b) allowing the —SMe group obtained in the step (a) to react with a cyanizing agent to produce a reaction intermediate; and (c) converting the reaction intermediate obtained in the step (b) to a peptide comprising an amino acid residue having an —OH group under more basic conditions than the conditions in the step (b). | 07-14-2011 |
20110213121 | NANOPARTICLE SENSOR FOR MEASURING PROTEASE ACTIVITY AND METHOD FOR MANUFACTURING THE SAME - Disclosed are a nanoparticle sensor for measuring protease activity, for protease imaging, and a method for preparing the same. More specifically, the present invention relates to a nanoparticle sensor for measuring protease activity in which a fluorophore- and a quencher-conjugated peptide substrate is conjugated to a biocompatible polymer nanoparticle. The peptide substrate is specifically lysed by a protease. The sensor according to the present invention is capable of inhibiting emission of fluorescence with high extinctive activity of the quencher on a fluorescent material. But strong fluorescence is specifically emitted only if the peptide substrate is lysed by a specific protease. Therefore, the sensor is especially useful as a method for screening a novel drug such as a protease overexpression inhibitor, and early diagnosis of incurable diseases and various diseases such as autoimmune diseases including cancer, osteoarthritis, rheumatoid arthritis and dementia. | 09-01-2011 |
20110224405 | DEGRADABLE SUPPORTS FOR TIDE SYNTHESIS - According to the present invention, there is provided a process for synthesis of a first compound selected from peptides, oligonucleotides, and peptide nucleic acids, which comprises synthesis of the first compound linked to a soluble support, wherein the soluble support is degraded following the synthesis so that it can be separated from the first compound. | 09-15-2011 |
20110237775 | METHODS FOR CHARACTERIZING GLYCOPROTEINS AND GENERATING ANTIBODIES FOR SAME - The invention provides methods for preparing a peptide useful in generating an antibody specific for the glycosylated form of a glycopolypeptide wherein the glycosylated portion is isolated and a peptide corresponding to amino acids adjacent to a glycosylated N-linked glycosylation site is prepared. | 09-29-2011 |
20110245460 | SOLVENT RESISTANT DIAFILTRATION OF PEPTIDES, PNA OR OLIGONUCLEOTIDES - According to the present invention, there is provided a process for the preparation of a first compound selected from peptides, oligonucleotides and peptide nucleic acids. The process comprises synthesising the first compound and then separating the first compound formed in step (i) from a second compound, which is a reaction by-product of the synthesis of the first compound and/or an excess of a reagent used for the synthesis of a first compound by a process of diafiltration. The membrane used for the diafiltration process is stable in organic solvents and provides a rejection for the first compound which is greater than the rejection for the second compound. | 10-06-2011 |
20110275785 | HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA - The present invention is directed to methods of transfecting cells with siRNA, by contacting a transfection complex with one or more cells, where the transfection complex includes a transport polymer and siRNA. The transport polymer may include for example, H | 11-10-2011 |
20110275786 | PROCESS FOR PURIFYING VANCOMYCIN WET BODY - Provided is a process for purifying a vancomycin wet body, comprising: dissolving a wet body obtained from a microorganism-fermented solution containing vancomycin into a water soluble solvent to a concentration of about 1 to 40 g/L and carrying out reverse osmosis filtration; and carrying out lyophilization of the filtered vancomycin. The process for purifying a vancomycin wet body provides high-purity vancomycin, while avoiding degradation of stability during a drying step. | 11-10-2011 |
20110282028 | METHOD FOR IDENTIFYING INHIBITORS OF LIPOTEICHOIC ACID SYNTHASE - The invention provides a method of identifying an inhibitor of LtaS comprising:
| 11-17-2011 |
20110294979 | METHODS FOR ISOLATING BACTERIA - The present invention relates to compositions and methods to identify novel bacteria and metabolites derived therefrom. More specifically, the invention describes a novel method to isolate bacteria producing metabolites of interest from environmental samples. Particularly, the invention discloses a method to select rare antibiotic producing bacteria. The invention can be used from any sample and allows the isolation of bacteria having e.g., pharmaceutical or agrochemical interest. | 12-01-2011 |
20110319592 | Process for the Purification of Antibodies Using Affinity Resins Comprising Specific Ligands - The present invention relates to a novel process for the purification of antibodies, e.g. monoclonal antibodies. The process utilizes an affinity resin comprising a solid phase material having immobilized thereto one or more low-molecular weight synthetic ligands. The affinity resins enable the separation of antibodies from even closely related proteins. | 12-29-2011 |
20120029165 | Methods and Compositions Involving Whey Protein Isolates - The present invention concerns methods of isolating milk proteins. Methods of the invention include charged ultrafiltration processes that use variations in pH to further separate protein species. | 02-02-2012 |
20120029166 | LINKERS AND CO-COUPLING AGENTS FOR OPTIMIZATION OF OLIGONUCLEOTIDE SYNTHESIS AND PURIFICATION ON SOLID SUPPORTS - A method of modulation of synthesis capacity on and cleavage properties of synthetic oligomers from solid support is described. The method utilizes linker molecules attached to a solid surface and co-coupling agents that have similar reactivities to the coupling compounds with the surface functional groups. The preferred linker molecules provide an increased density of polymers and more resistance to cleavage from the support surface. The method is particularly useful for synthesis of oligonucleotides, oligonucleotides microarrays, peptides, and peptide microarrays. The stable linkers are also coupled to anchor molecules for synthesis of DNA oligonucleotides using on support purification, eliminating time-consuming chromatography and metal cation presence. Oligonucleotides thus obtained can be directly used for mass analysis, DNA amplification and ligation, hybridization, and many other applications. | 02-02-2012 |
20120035345 | PROCESS FOR PREPARING GLYCOPEPTIDES HAVING ASPARAGINE-LINKED OLIGOSACCHARIDES, AND THE GLYCOPEPTIDES - Glycopeptide having at least one asparagine-linked oligosaccharide at a desired position of the peptide chain obtained by:
| 02-09-2012 |
20120059147 | METHOD FOR SITE-SELECTIVELY CLEAVING TARGET NUCLEIC ACID - There is provided a method for cleaving a target nucleic acid at a desired site using a metal ion or a metal ion complex as a catalyst for cleaving a nucleic acid (DNA, etc.), which has high site-selectivity, high reaction efficiency and low side-reactivity (non-specific reactivity), and is economical and convenient. The method for cleaving a target nucleic acid of the present invention comprises allowing a target nucleic acid to come into contact with a specific complex compound and a metal ion or a metal complex, or allowing a target nucleic acid to come into contact with a specific complex compound, to which a metal ion or a metal complex binds. | 03-08-2012 |
20120065368 | CYCLODEXTRIN-BASED POLYMERS FOR THERAPEUTICS DELIVERY - The present invention relates to novel compositions of therapeutic cyclodextrin containing polymeric compounds designed as a carrier for small molecule therapeutics delivery and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods of treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business comprising manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein. | 03-15-2012 |
20120101254 | FUNCTIONALISING REAGENTS AND THEIR USES - Reagents and methods for functionalising polypeptides with moieties poly (alkylene glycol) molecules and glycan groups are disclosed that are based on a functionalising reagent which comprises a nitrogen containing heterocyclic aromatic ring having a vinyl substituent that is capable of reacting with one or more thiol groups that are naturally present, or have been introduced into, the polypeptide, for example by employing a thiol group of one or more cysteine residues. The functionalising reagent is covalently linked to a poly (alkylene glycol) molecule, such as a polyethylene glycol (PEG) molecule, or a glycan group so that the reaction between the vinyl group and the thiol group in the polypeptide covalently links the polypeptide to the poly (alkylene glycol) molecule and/or the glycan group. | 04-26-2012 |
20120149869 | ALPHA-CONOTOXIN PEPTIDES - The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. | 06-14-2012 |
20120165504 | VANCOMYCIN B HYDROCHLORIDE CRYSTALLINE FORM 1 - Vancomycin B Hydrochloride Crystalline Form 1, compositions containing it and methods of prevention or treatment of bacterial infections using it are disclosed. | 06-28-2012 |
20120238723 | PRODUCTION METHOD OF 11-SUGAR SIALYLGLYCOPEPTIDE - It is an object of the present invention to provide a method for producing an 11-sugar sialylglycopeptide easily and with good yield and a high degree of purity on an industrial scale from defatted bird egg yolks. The present invention provides a production method of an 11-sugar sialylglycopeptide. More specifically, the present invention provides a production method of an 11-sugar sialylglycopeptide comprising: an extraction step of extracting defatted bird egg yolks with water or a salt solution to obtain a liquid extract of a glycopeptide, a precipitation step of adding the liquid extract to a water-soluble organic solvent to precipitate the glycopeptide, and a desalting step of desalting the precipitate. | 09-20-2012 |
20120238724 | MUTATED IMMUNOGLOBULIN-BINDING PROTEIN - The present invention relates to an immunoglobulin-binding protein, wherein at least one asparagine residue has been mutated to an amino acid other than glutamine or aspartic acid, which mutation confers an increased chemical stability at pH-values of up to about 13-14 compared to the parental molecule. The protein can for example be derived from a protein capable of binding to other regions of the immunoglobulin molecule than the complementarity determining regions (CDR), such as protein A, and preferably the B-domain of Staphylococcal protein A. The invention also relates to a matrix for affinity separation, which comprises an immunoglobulin-binding protein as ligand coupled to a solid support, in which protein ligand at least one asparagine residue has been mutated to an amino acid other than glutamine. | 09-20-2012 |
20120245323 | OXIDIZED DERIVATIVE OF HYALURONIC ACID, A METHOD OF PREPARATION THEREOF AND A METHOD OF MODIFICATION THEREOF - The invention relates to a hyaluronic acid derivative and methods of preparation and modification of a hyaluronan derivative with an aldehydic group in the position (6) of the polysaccharide glucosamine part. The oxidation of the hyaluronic acid can be performed by means of Dess-Martin periodinane (DMP) agent. The prepared aldehyde can be used for binding amine, diamine, amino acid, peptide and other compounds containing an amino group, e.g. by means of the reductive amination with NaBH | 09-27-2012 |
20120271032 | Preparation of a Therapeutic Composition - Product R, a novel therapeutic composition for treating viral infections and stimulating the immune system comprises a unique peptide having 31 amino acids and another unique peptide having 21 amino acids and connected with an oligo-nucleotide through a diphosphodiester or diphosphodithioate ester linkage. The composition has a light absorption spectrum with typical absorption ratios of 1.998 at 260 mn/280 nm and 1.359 at 260 nm/230 nm. | 10-25-2012 |
20120271033 | HIGH AFFINITY ADAPTOR MOLECULES FOR REDIRECTING ANTIBODY SPECIFITY - Disclosed are methods for identifying high affinity adaptor molecules that bind to both a circulating antibody and a target molecule and redirect the specificity of the circulating antibody to the target molecule. Exemplary high affinity adaptor molecules are also provided. | 10-25-2012 |
20130023643 | NUCLEAR LOCALIZATION SIGNAL PEPTIDES DERIVED FROM VP2 PROTEIN OF CHICKEN ANEMIA VIRUS AND USES OF SAID PEPTIDES - Disclosed herein are isolated peptides having nuclear localization activity and derived from the VP2 protein of chicken anemia virus (CAV). The isolated peptides are proven to be useful and effective in the nuclear delivery of a selected target substance, such as proteins, peptides, nucleic acids, pharmaceutically active agents, chemical substances, etc. The isolated peptide can transport a target substance, in particular a protein, into the nucleus of a mammalian cell by forming a conjugate with the target substance, or via an expression cassette capable of expressing a fusion protein having the isolated peptide and the target protein. | 01-24-2013 |
20130030151 | RAPID GLYCOPEPTIDE OPTIMIZATION VIA NEOGLYCOSYLATION - The present invention generally relates to methods and compositions for generating vancomycin analogs. Specifically the invention relates to generating a vancomycin library through chemoselective ligation of a sugar moiety with a vancomycin aglycon. In particular, the present invention provides a library of vancomycin analogs, where the member of the library comprises at least one vancomycin analog selected from 2′-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 3′-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 4′-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 6′-N-acyldecanoyl-glucosyl vancomycin neoglycoside, 2′-N-acylbiphenyl-glucosyl vancomycin neoglycoside, 3′-N-acylbiphenoyl-glucosyl vancomycin neoglycoside, 4′-N-acylbiphenoyl-glucosyl vancomycin neoglycoside and 6′-N-acylbiphenoyl-glucosyl vancomycin neoglycoside. | 01-31-2013 |
20130041131 | GLYCOSYLATED SPECIFICITY EXCHANGERS - The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein. | 02-14-2013 |
20130053543 | PEPTIDE CLEARING AGENTS - A peptide clearing agent is provided for clearance of a conjugate of an enzyme and a binding molecule which binds specifically at a target location from a non-target location in a subject. The peptide clearing agent binds the active site of the enzyme. The peptide also binds to the asialoglycoprotein receptor expressed by hepatic cells to facilitate clearance through the liver. The peptide may be glycosylated to facilitate clearance through the liver by binding to hepatic cells expressing an asialoglyco-protein receptor. Typically, the peptide prevents or inhibits enzyme activity upon binding to the enzyme and is not substantially modified by the enzyme activity. The peptide may be based upon the dipeptide amino-naphthoic acid (ANA)-glutamate (GIu) and may comprise the amino acid sequence serine (Ser)-Alanine (Ala)-amino-naphthoic acid (ANA)-glutamate (GIu). In such cases, the enzyme of interest is typically CPG2. | 02-28-2013 |
20130072659 | Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites - The present invention concerns methods and compositions for delivery of therapeutic agents to target cells, tissues or organisms. In preferred embodiments, the therapeutic agents are delivered in the form of therapeutic-loaded polymers that may comprise many copies of one or more therapeutic agents. In more preferred embodiments, the polymer may be conjugated to a peptide moiety that contains one or more haptens, such as HSG. The agent-polymer-peptide complex may be delivered to target cells by, for example, a pre-targeting technique utilizing bispecific or multispecific antibodies or fragments, having at least one binding arm that recognizes the hapten and at least a second binding arm that binds specifically to a disease or pathogen associated antigen, such as a tumor associated antigen. Methods for synthesizing and using such therapeutic-loaded polymers and their conjugates are provided. | 03-21-2013 |
20130096275 | VANCOMYCIN B HYDROCHLORIDE CRYSTALLINE FORM 1 - Vancomycin B Hydrochloride Crystalline Form 1, compositions containing it and methods of prevention or treatment of bacterial infections using it are disclosed. | 04-18-2013 |
20130131312 | PEPTIDE CONJUGATED, INOSINE-SUBSTITUTED ANTISENSE OLIGOMER COMPOUND AND METHOD - A therapeutic oligomer-peptide conjugate, and methods of using the conjugate are disclosed. The conjugate includes (a) a substantially uncharged oligonucleotide analog compound having a base sequence that includes a string of bases that are complementary to four or more contiguous cytosine bases in a target nucleic acid region to which the compound is intended to bind, and (b) conjugated to the compound, an arginine-rich peptide effective to enhance the uptake of the compound into target cells. The string of bases in the compound includes at least one inosine base positioned in the string so as to limit the number of contiguous guanine bases in said string to three or fewer. The conjugate has greater cellular uptake than the compound alone, by virtue of the arginine-rich peptide, and substantially greater antisense activity greater activity than the conjugate in the absence of inosine-for guanine substitutions. | 05-23-2013 |
20130137850 | NOVEL POLYMER AND PROCESS FOR PRODUCING THE SAME - An objective of the invention is to provide an excellent biomaterial having a good operability and a high safety; the solution is a polymer having one or more peptide units represented by formula (1) as described below and one or more saccharide residues derived from polysaccharides: | 05-30-2013 |
20130172528 | DALBAVANCIN COMPOSITIONS FOR TREATMENT OF BACTERIAL INFECTIONS - The invention provides methods for drying dalbavancin. The method includes providing wet dalbavancin that includes dalbavancin, water, and a solvent. The wet dalbavancin is dried at at a temperature of about 30° C. or less, at a vacuum pressure of about 50 mbar or less, until the water level of the wet dalbavancin is less than about 20% (w/w). Water is then added to the dalbavancin and the resulting wet dalbavancin is dried at least once more at a temperature of about 30° C. or less, at a vacuum pressure of about 50 mbar or less, until the solvent level of the dalbavancin is less than about 3.0% (w/w). | 07-04-2013 |
20130253168 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES - In an embodiment the instant invention discloses a modular composition comprising 1) an oligonueleotide; 2) one or more linkers, which may be the same or different, selected from Table 1, wherein the linkers are attached to the oligonucleotide at the 2′-position of the ribose rings and/or the terminal 3′- and/or 5′-positions of the oligonucleotide; 3) optionally, one or more peptides, which may be the same or different, selected from SEQ ID NOs: 1-59, wherein the peptides are attached to the linkers; and optionally one or more lipids, solubilizing groups and/or targeting ligands attached to the oligonucleotide. | 09-26-2013 |
20130267678 | TRANSCRIPTOME IN VIVO ANALYSIS - Provided are compositions and methods that permit a hybrid nucleic acid-peptide molecule to enter a cell and when specifically activated within the cell, the molecule anneals to endogenous cellular RNA and permits the isolation of the RNA. | 10-10-2013 |
20130281658 | Peptide-Based In Vivo siRNA Delivery System - The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides. | 10-24-2013 |
20130303727 | VANCOMYCIN B HYDROCHLORIDE CRYSTALLINE FORM 1 - Vancomycin B Hydrochloride Crystalline Form 1, compositions containing it and methods of prevention or treatment of bacterial infections using it are disclosed. | 11-14-2013 |
20130338338 | ALPHA-CONOTOXIN PEPTIDES - The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. | 12-19-2013 |
20140011977 | CHIMERIC MOLECULES TO MODULATE GENE EXPRESSION - The present invention provides a chimeric molecule including a base-pairing segment that binds specifically to a single-stranded nucleic acid molecule; and a moiety that modulates splicing or translation. The invention also provides a chimeric molecule including a base-pairing segment that binds specifically to a double-stranded nucleic acid molecule; and a peptide that modulates transcription, wherein the peptide comprises up to about one hundred amino acid residues. | 01-09-2014 |
20140058062 | Method for Producing Glycopeptide Having Sialyl Sugar Chain, Sialyl Sugar Chain-Added Amino Acid Derivative to be Used in Same, and Glycopeptide - [Technical Promblem] | 02-27-2014 |
20140066592 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASES - The present invention relates to methods and compositions for the treatment of diseases, including cancer, infectious diseases and autoimmune diseases. The present invention also relates to methods and compositions for improving immune function. More particularly, the present invention relates to multifunctional molecules that are capable of being delivered to cells of interest for the treatment of diseases and for the improvement in immune function. | 03-06-2014 |
20140163200 | Method for determining an unknown PNA sequence and uses thereof - The invention relates to a method for the sequence information of PNA molecules of a specific PNA molecule species, wherein, the PNA molecules are contacted with different nucleic acid molecule species comprising nucleic acid molecules with nucleotides, wherein the nucleic acid molecules partially comprise a nucleic acid sequence that is complementary to a partial sequence of the PNA molecule, wherein nucleic acid molecules having complementary sequences bind to the PNA molecules forming nucleic acid/PNA hybrids, wherein nucleic acid molecules with non-complementary sequences are separated from the hybrids, wherein thereafter the hybrids are dissociated into single stranded hybrid nucleic acid molecules and PNA molecules, wherein the single stranded hybrid nucleic acid molecules are subjected to a sequencing process providing hybrid sequence information about the single stranded hybrid nucleic acid sequence, and wherein the hybrid sequence information is optionally translated into the complementary PNA sequence information. | 06-12-2014 |
20140171618 | METHOD FOR PREPARING MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE CONJUGATES - The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B) | 06-19-2014 |
20140187742 | Methods for Purifying Pertussis Toxin and Peptides Useful Therefor - The present invention relates to reagents and methods for purifying pertussis toxin (PT). | 07-03-2014 |
20140213758 | VERSATILE NATIVE CHEMICAL LIGATION TECHNOLOGIES - Novel methods of native chemical ligation are provided. The methods involve reacting a thioacid (e.g. a peptide thioacid) with an aziridinyl compound (e.g. an aziridinyl peptide) or glycosylamine under mild conditions without the use of protecting groups, and without requiring that a cysteine residue be present in the ligation product. Initial coupling of the thioacid and the aziridinyl compound yields a ligation product containing an aziridinyl ring. Optional subsequent opening of the aziridinyl ring (e.g. via a nucleophilic attack) produces a linearized and modified ligation product. Coupling of a peptide thioacid and glycosylamine yields a glycosylated peptide. | 07-31-2014 |
20140235822 | METHOD FOR PRODUCING PEPTIDE - The present invention provides a method for producing a peptide, characterized in that it comprises converting an —SH group of a peptide comprising an amino acid residue having the —SH group to an —OH group, wherein said method comprises the following steps (a) to (c): (a) allowing an —SH group in a peptide to react with a methylating agent to convert the —SH group to an -SMe group; (b) allowing the -SMe group obtained in the step (a) to react with a cyanizing agent to produce a reaction intermediate; and (c) converting the reaction intermediate obtained in the step (b) to a peptide comprising an amino acid residue having an —OH group under more basic conditions than the conditions in the step (b). | 08-21-2014 |
20140249293 | Absent and Rare Peptides and Therapeutic Uses Thereof - The present invention relates to methods for searching and identifying absent and rare peptide sequences from public databases and their uses in the treatment of pathological diseases. One embodiment of the present invention provides a method that includes: a) storing, in a memory or storage of a computing device, a set of at least one peptide sequence of fixed length; b) searching, by the computing device, for a peptide sequence from the set within at least one database having naturally-occurring amino acid sequences; and c) classifying, by the number of appearance in the database, the peptide sequence. | 09-04-2014 |
20140256911 | PREPARATION OF OLIGO CONJUGATES - Conjugated molecules are prepared that comprise a predetermined number of oligo conjugation components. The conjugated molecules also may comprise one or more detectable labels. Preparation of these molecules can be implemented according to an asymmetric or a symmetric conjugation strategy. | 09-11-2014 |
20140288267 | COMPOSITIONS AND METHODS FOR MODULATING RSV INFECTION AND IMMUNITY - Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif. | 09-25-2014 |
20140323688 | Chemical Reagents for the Activation of Polysaccharides in the Preparation of Conjugate Vaccines - This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (CPPT), 1-cyano-imidazole (1-CI), 1-cyanobenzotriazole (1-CBT), or 2-cyanopyridazine-3(2H)one (2-CPO), or a functional derivative or modification thereof. The examples illustrate the use of these reagents with a variety of polysaccharides and proteins showing that the methods are generally applicable. | 10-30-2014 |
20140350217 | FUNCTIONAL LIPID CONSTRUCTS - The invention relates to methods for effecting qualitative and quantitative changes in the functional moieties expressed at the surface of cells and multi-cellular structures, and functional lipid constructs for use in such methods. In particular, the invention relates to functional lipid constructs and their use in diagnostic and therapeutic applications, including serodiagnosis, where the functional moiety is a carbohydrate, peptide, chemically reactive group, conjugator or fluorophore. | 11-27-2014 |
20140350218 | ALPHA-CONOTOXIN PEPTIDES - The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. | 11-27-2014 |
20140357839 | VANCOMYCIN B HYDROCHLORIDE CRYSTALLINE FORM 1 - Vancomycin B Hydrochloride Crystalline Form 1, compositions containing it and methods of prevention or treatment of bacterial infections using it are disclosed. | 12-04-2014 |
20140378652 | METHOD FOR PREPARING MULTIPLE ANTIGEN GLYCOPEPTIDE CARBOHYDRATE CONJUGATES - The present invention relates to a method for preparing carbohydrate T cell epitope conjugates of formula (I): M(T-B) | 12-25-2014 |
20150025220 | NUCLEOSIDES WITH ANTIVIRAL AND ANTICANCER ACTIVITY - The invention provides a compound of formula I: | 01-22-2015 |
20150087806 | GLYCOPEPTIDE AND USES THEREOF - A glycolipopeptide comprising a carbohydrate component, a peptide component and a lipid component, for use as a therapeutic or prophylactic vaccine. Also provided are monoclonal and polyclonal antibodies that recognize the glycolipopeptide of the invention, as well as uses thereof. | 03-26-2015 |
20150133631 | Compositions and Methods for Conjugating Oligonucleotides - An oligonucleotide derivative having the structure of formula (A) and methods for preparing the oligonucleotide derivative are disclosed. wherein R | 05-14-2015 |
20150322120 | SODIUM CHANNEL SENSITIVE CONOPEPTIDES AND ANALOGS, INCLUDING COMPOSITIONS AND METHODS THEREOF - The present invention relates to conopeptides that are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which block the sodium channels. | 11-12-2015 |
20150352221 | Peptide-Based In Vivo siRNA Delivery System - The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted melittin delivery peptides. Delivery peptides provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery peptides. | 12-10-2015 |
20150353592 | FUNCTIONALIZATION AND PURIFICATION OF MOLECULES BY REVERSIBLE GROUP EXCHANGE - Embodiments of the present disclosure include methods and compositions for functionalizing molecules, such as oligonucleotides, with functional groups, including polyhistidine tags useful in affinity methods. Some embodiments include methods for modifying and purifying complex mixtures of molecules by exchange of functional tags. | 12-10-2015 |
20150374843 | MULTIVALENT CONSTRUCTS FOR THERAPEUTIC AND DIAGNOSTIC APPLICATIONS - The invention provides compositions and methods for therapeutic and diagnostic applications. | 12-31-2015 |
20160074525 | NOVEL SINGLE CHEMICAL ENTITIES AND METHODS FOR DELIVERY OF OLIGONUCLEOTIDES - In an embodiment the instant invention discloses a modular composition comprising 1) an oligonucleotide; 2) one or more linkers, which may be the same or different, selected from Table 1, wherein the linkers are attached to the oligonucleotide at the 2′-position of the ribose rings and/or the terminal 3′- and/or 5′-positions of the oligonucleotide; 3) optionally, one or more peptides, which may be the same or different, selected from SEQ ID NOs: 1-59, wherein the peptides are attached to the linkers; and optionally one or more lipids, solubilizing groups and/or targeting ligands attached to the oligonucleotide. | 03-17-2016 |
20160102307 | OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA - Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin. | 04-14-2016 |
20160120998 | Cell-Penetrating Drug Carrier and the Application Thereof - This invention is about a cell-penetrating drug carrier and the application thereof. The mentioned cell-penetrating drug carrier can approach the target cell through using a proper recognizable sequence, so that the cell-penetrating drug carrier can be used to specifically delivery wanted drug to target cell. Through carrying wanted drug into the cytoplasm of the target cell by cell-penetrating peptide, the drug accumulation volume in the target cell can be efficiently increased. Preferably, through using proper bioinert polymer, the cell-penetrating peptide and the recognizable sequence can be kept from been digested before approaching the target cell. | 05-05-2016 |
20160121004 | NOVEL GRP-R AGONISTIC 177-LUTETIUM-LABELED BOMBESIN DERIVATIVES FOR DIAGNOSIS AND TREATMENT OF PROSTATE CANCER - Provided is a novel compound capable of being usefully used to diagnose and treat prostate cancer by labeling a radioisotope on a bombesin derivatives capable of selectively targeting a target material over-expressed in tumor cells in order to develop an effective diagnose and treatment method of diseases associated with prostate cancer. | 05-05-2016 |
20160129150 | SUGAR CHAIN-POLYPEPTIDE COMPLEX - The object of the present invention is to provide a sugar chain-polypeptide complex that may form a transparent and homogeneous hydrogel in a broad pH. The present invention provides a sugar chain-polypeptide complex, characterized in that said polypeptide is a polypeptide comprising an amino acid sequence consisting of 8-34 amino acid residues in which polar and nonpolar amino acid residues are alternately arranged, and one or more sugar chains are bound to said polypeptide. | 05-12-2016 |
20160168183 | Conjugates Containing Hydrophilic Spacer Linkers | 06-16-2016 |
20160168204 | METHOD FOR PURIFYING OLIGOSACCHARIDE PEPTIDE | 06-16-2016 |
20160168636 | NUCLEOTIDE ANALOGS | 06-16-2016 |
20160251400 | HIGH AFFINITY ADAPTOR MOLECULES FOR REDIRECTING ANTIBODY SPECIFITY | 09-01-2016 |
20190144511 | Modified Kappa Light Chain-Binding Polypeptides | 05-16-2019 |